Intas has developed a biosimilar of Lucentis, which is currently under Phase III global trial for submission in major countries including EMA & the US
Among patients with infectious virus at baseline, no patients who received Lagevrio had infectious virus at days 3, 5 or 10
Company announced that it is accelerating its investment in its Leaps by Bayer impact investment unit with more than 1.3 billion euros funding until end of 2024
The brand Azmarda fits well with JBCPL's overall strategy of strengthening its presence in the cardiology segment in India.
This state-of-art technology will help pulmonologists to diagnose lung cancer in the very early stages helping the patient get an early surgical resection
Yescarta is First CAR T-cell therapy to receive NCCN treatment guideline category 1 recommendation --
The launch of medical cannabis products resulted from an agreement between the two companies signed in 2021
The Cidmus brand shall be affixed on the pharmaceutical composition comprising a combination of Valsartan and Sacubitril (currently under Novartis patent) which is indicated for heart failure patients with reduced ejection fraction
Celerity Pharmaceuticals uses Biocon Biologics’ insulin drug substance to develop the product
The new structure further transitions the Health Care business line into a system solutions partner for the pharmaceutical and biotech industries
Subscribe To Our Newsletter & Stay Updated
